Our observation demonstrated that deletion of FBXO22 significantly prevented MLL-AF9-induced AML leukemogenesis and reduced the number of LSCs in AML mice by inducing apoptosis, indicating that FBXO22 functions as an oncoprotein that critically involved in the development of AML. Here, KMT2A is linked to acute myeloid leukemia.